SPONSOR
Istituto Clinico Humanitas
Total Trials
9
Recruiting
9
Phases
Phase 2
Conditions studied: Diffuse Large B-Cell LymphomaHigh-grade B-cell Lymphoma (HGBCL)B-Cell Lymphoma TreatmentRelapsed or Refractory LymphomaOligometastatic DiseaseCancerZenker DiverticulumDeveloping Acute Respiratory Distress SyndromeProton TherapyCritical Illness Polyneuromyopathy
Istituto Clinico Humanitas is a clinical research sponsor with 9 registered studies on ClinicalTrials.gov, of which 9 are actively recruiting participants. Research covers conditions including Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), B-Cell Lymphoma Treatment, Relapsed or Refractory Lymphoma.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Istituto Clinico Humanitas
How many clinical trials has Istituto Clinico Humanitas sponsored?
ClinicalMetric currently tracks 9 clinical trials sponsored by Istituto Clinico Humanitas, of which 9 are actively recruiting participants. These trials cover conditions including Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), B-Cell Lymphoma Treatment. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Istituto Clinico Humanitas research focus on?
Istituto Clinico Humanitas clinical trials span Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), B-Cell Lymphoma Treatment, Relapsed or Refractory Lymphoma, Oligometastatic Disease, and additional conditions. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Istituto Clinico Humanitas clinical trial?
To participate in a Istituto Clinico Humanitas trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Istituto Clinico Humanitas trials with current recruitment status updated daily.
Clinical Trials by Istituto Clinico Humanitas
NCT06918912 Phase 2
Recruiting
Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure
Diffuse Large B-Cell Lymphoma
NCT05903261
Recruiting
Prospective Observational Basket Study of Stereotactic Body Radiation Therapy for OligoMetastatic Patients From Rare Tumors
Oligometastatic Disease
NCT07098247
Recruiting
Exploring Photon-Counting CT for Enhanced Target Delineation and Dose Accuracy in Personalized Radiotherapy - ANTHEM
Cancer
NCT03948438
Recruiting
Endoscopic Treatment for Zenker's Diverticulum
Zenker Diverticulum
NCT07686315
Recruiting
Advanced Respiratory Monitoring for Safer Mechanical Ventilation in Patients Without Respiratory Failure
Developing Acute Respiratory Distress Syndrome
NCT07317245
Recruiting
HUmanitas PROtontherapy (HU-PRO)
Cancer
NCT07478367
Recruiting
Critical Illness Weakness Outside the Intensive Care Unit.
Critical Illness Polyneuromyopathy
NCT07299357
Recruiting
Prospective Observational Trial of Image-guided Ablative STereotactic bOdy Radiation Therapy for Primary kidNey Cancer: the STONE Trial
Renal Cancer
NCT07635641
Recruiting
REPROton-HN: Prospective Observational Study on Proton Re-irradiation for Locoregional Recurrences of Head and Neck Tumors
Head & Neck Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology